Durable Responses With PD-1 Inhibition in Lung and Kidney Cancer and the Ongoing Search for Predictive Biomarkers.
Dana-Farber Cancer Institute, Boston, MA.
Mark M
MM
Awad
Dana-Farber Cancer Institute, Boston, MA peter_hammerman@dfci.harvard.edu.
Peter S
PS
Hammerman
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents